SignalXSignalX

Immunome Inc. (IMNM) Q3 2025 10-Q Quarterly Report

Filed: Nov 6, 2025Period ending Sep 30, 2025
Health Care
Pharmaceutical PreparationsSEC EDGAR
Immunome Inc. Overview

Immunome Inc. (IMNM) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 6, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

Immunome Inc. Q3 2025 10-Q Analysis

Risk Factors

  • • New risk due to recent acquisition of varegacestat, Phase 3 asset requiring additional clinical data before NDA submission
  • • Updated risk on capital sufficiency: cash expected to fund operations for ≥12 months from filing date amid volatile credit markets
+3 more insights

Immunome Inc. Q3 2025 Quarterly Financials
XBRL

Revenue

$0

▼ -100.0% YoY▼ -100.0% QoQ

Net Income

-$57M

▼ -22.0% YoY▼ -32.4% QoQ

ROE

-21.8%

Total Assets

$299M

EPS (Diluted)

$-0.66

▲ +12.0% YoY▼ -32.0% QoQ

Operating Cash Flow

-$41M

▼ -18.6% YoY▲ +18.0% QoQ

Source: XBRL data from Immunome Inc. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Get deeper insights on Immunome Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.